PROFESSIONAL BOARD FOR EMERGENCY CARE

Transcription

1 PROFESSIONAL BOARD FOR EMERGENCY CARE IMPORTANT NOTICE TO ALL EMERGENCY CARE PRACTITIONERS INTRODUCTION OF NEW SCOPE OF PRACTICE FOR REGISTERED EMERGENCY CARE PRACTITIONERS NOVEMBER 2009 Herewith the July 2009 approved Scope of Practice for Registered Emergency Care Practitioners as approved by the Professional Board for Emergency Care. It is imperative that you familiarize yourself with the entire content thereof and is supplemental to the Paramedic Protocols It is the duty of every practitioner to maintain and update their knowledge and skills through active participation in continuing professional development activities. Any comments or enquiries in this regard can be directed in writing or via to the Senior Board Manager of the Professional Board for Emergency Care. 1. WORKSHOP / SEMINAR All persons currently registered as Emergency Care Practitioners (ECP) are required to participate in a program that will include update practice and knowledge of the additional skills. It is envisaged that the said program will be facilitated by the higher education institutions (HEIs) currently offering the Bachelor of Technology: Emergency Medical Care program. You will be notified of these programs updates in due course by the respective HEIs. Please note that this update program is compulsory and will include theoretical and practical assessments. Experiential exposure is required in the authentic environment (theatre and coronary care units). A portfolio of evidence will be required to be submitted to the respective HEI for assessment and approval prior to practise. The names of all successful attendees will be submitted to the Professional Board for Emergency Care. 2. CONSULTATION Every ECP must consider consultation for safe practice and to improve clinical decision making in the early stages of the practice of ECP skills. As an example, for the practice of fibrinolysis, this will involve the establishment of a cardiac care network, consisting of local cardiologists / specialists within the local hospitals for direct admission to intensive care facilities.

2 3. CONTINUING QUALITY ASSURANCE, QUALITY CONTROL AND PERFORMANCE REVIEW Ongoing quality assurance must take the form of periodic performance review by a locally established review panel comprising of peers and specialists in the respective clinical areas. Furthermore, it is recommended that ECPs annually attend CPD activities to ensure current competence. 4. PATIENT RECORD DATABASE Patient record database have been set up for monitoring of all advanced airway management cases requiring RSI and fibrinolysis by ECPs. These databases will be hosted at the Durban University of Technology and will soon take the form of an on-line database. Every ECP must submit all the relevant cases to the respective database. These submissions will currently take the form of a faxed case report form to the following fax numbers: Emergency Care Practitioner: Airway Management: Emergency Care Practitioner: Fibrinolysis: SPECIAL SKILL REQUIREMENTS The following is mandatory for the safe practice of the respective skills: RAPID SEQUENCE INTUBATION Secondary confirmation device/s Portable mechanical ventilator that allows adjustment of tidal volume and respiratory rate Portable qualitative/quanatative end-tidal carbon dioxide monitoring that allows targeted ventilation to normalised end tidal C02 Portable Sp02 monitor Consultation with a specialist clinician with training / experience in RSI must be considered All cases of RSI are to be subjected to case review FIBRINOLYSIS 12 lead ECG monitor with data transmission capability. Volumetric infusion device (unless Tenecteplase and Enoxaparin are going to be administered infusion pump required for heparin and Streptokinase) Consultation with a specialist clinician with training / experience in STEMI management must be considered All cases of thrombolysis are to be subjected to case review

3 UPDATED LIST OF APPROVED MEDICINES FOR EMERGENCY CARE PRACTITIONERS AS AT JULY 2009 PLATELET AGGREGATION INHIBITOR Acetyl Salicylic Acid (Aspirin) Classification : Platelet aggregation inhibitor Clopidogrel Classification : Platelet aggregation inhibitor ABSORBANT Activated Charcoal Classification : Carbon ANTI ARRHYTHMICS Adenosine Classification : Endogenous Purine Nucleoside/Supraventricular Anti Arrhythmic Amiodarone Classification : Class III Anti arrhythmic/atrial & Ventricular Lignocaine Hydrochloride (Systemic) Classification : Class I B- Ventricular Anti Arrhythmic LOCAL ANAESTHETIC Lignocaine Hydrochloride 2% Xylocaine Spray Lignocaine Topical Spray Classification : Amide Group/ Topical/ Local Anaesthetic

4 ADRENERGIC Adrenaline/ Epinephrine Classification : Sympathomimetic Catecholamine ANTI-CHOLINERGIC Atropine Classification : Competitive Anti-Cholinergic Schedule : 2 Ipratropium Bromide Classification : Inhalant Bronchodilator (atropine derivative anti-cholinergic) SELECTIVE BETA2 AGONISTS (INHALED) Salbutamol Feneterol Classification : Bronchodilators Schedule : 2 (Aerosol); 3 (Inhalant Solution) SELECTIVE BETA2 AGONISTS (SYTEMIC) Salbutamol Hexoprenaline Classification : Intravenous Bronchodilator MINERAL SUPPLEMENT/ ELECTROLYTE Calcium Chloride 10% Classification : Positive inotrope- peri- cardiac and cardiac arrest where Electrolyte electroyte disturbance (hyperkalaemia is suspected or known) Mineral Supplement Sodium Bicarbonate 8.5% Classification : Electrolyte / Mineral Supplement

5 OTHER MINERAL SUPPLEMENT Magnesium sulphate Classification : Mineral supplement; prevention and control of seizures and hypertension in toxaemia of pregnancy, in the management of serve asthma and for the treatment of VT with/without a pulse CORTICOSTEROIDS Hydrocortisone Methylprednisolone Classification : Glucocorticoid / Steroidal Anti- Inflammatory CARBOHYDRATES Dextrose 5%- 50% Classification Oral Glucose Powder/ Gel : Parenteral Nutrition / Acute Symptomatic Hypoglycaemic Treatment HYPERGLYCAEMIC AGENT Glucagon Classification : Hyperglycaemic agent and for the treatment of bradycardia/hypotension associated with a proven/suspected Beta Blocker over-dose BENZODIAZEPINE DERIVATIVE Diazepam Midazolam Lorazepam Classification : Anti-Convulsant/ Sedative/ Hypnotic BENZODIAZEPINE ANTAGONIST Flumazenil Classification : Benzodiazepine Antagonist HIGH CEILING LOOP DIURETIC Furosemide Classification : Diuretic

6 ORGANIC NITRATES Glyceryl Trinitrate Classification : Vasodilator ANTI- EMETIC Metoclopramide Monohydrochloride Classification : Propulsive Anti-emetic/ Dopamine Antagonist Cyclizine Classification : Piperazine-type Antihistamine Schedule : 2 NON-SELECTIVE ANTIHISTAMINE Promethazine Classification : Antihistamine ANALGESICS Morphine Sulphate Cyclimorph (morphine with cyclizine anti-emetic) Schedule : 7 Classification : Opium Alkaloids/ Opioid Analgesics OPIOID ANTAGONIST Naloxone Hydrochloride Classification : Pure Opioid Antagonist/ Narcotic Antagonist Nitrous Oxide Classification : Analgesic Gas OTHER GAS Medical Oxygen Classification : Concentrated Naturally Occurring Atmospheric Gas CO-ENZYME Thiamine (vitamin B1)/ Aneurine Classification : Nutritional supplement/ B group vitamin (emergency treatment of Wernicke s Encephalopathy and Beriberi)

7 THROMBOLYTIC AGENTS Streptokinase Tenecteplase Classification : Enzymes ANTITHROMBOTIC AGENTS Heparin Sodium Enoxaparin Classification : Anticoagulant INDUCTION AGENTS Ketamine Classification : Dissociative Anaesthesia/procedural sedation/ Analgesic/ Mild Bronchodilator Etomidate Classification : Induction Agent MUSCLE RELAXANTS (NEURO BLOCKING AGENTS) Suxamethonium Chloride Classification : Depolarizing Muscle Relaxant Vecuronium Rocuronium Classification : Non-Depolarizing Muscle Relaxants